logo
‘Extraordinary' increase in abuse aimed at GP teams, top medic says

‘Extraordinary' increase in abuse aimed at GP teams, top medic says

Yahoo13-02-2025
There has been an 'extraordinary' increase in abuse aimed at GP teams, which is contributing to family doctors leaving the profession, one of England's leading medics has suggested.
Dr Claire Fuller, primary care medical director for NHS England, said it is not acceptable to 'bash' GPs, who are 'exhausted' and working 'flat out'.
'When you talk to GPs about why they leave, they say one is about the workload and the other one is about respect,' Dr Fuller told the PA news agency.
She said 'from the respect point of view' the 'increase in violence to members of primary care teams is extraordinary that has happened, from attacks, both physical and verbal'.
Dr Fuller added: 'So if you think about practice managers, every day, will get a phone call from a patient that says, 'If I die today, it'll be your fault'.
'And these are people that are working part-time, on low incomes, that are receiving this level of abuse from the public.'
The comments come after a poll found more than 80% of GP teams in the UK have been verbally attacked by patients.
The Medical and Dental Defence Union of Scotland (MDDUS) surveyed 1,855 doctors in October 2024, with 690 GPs responding.
Of the family doctors that took part, some 84% said their team had suffered verbal abuse.
More than a quarter (28%) said they or their team had been the victim of physical violence from patients, while more than a third (35%) said they had suffered racial abuse and 15% told the poll they had been the victim of sexual abuse.
Dr John Holden, chief medical officer at the MDDUS, said: 'Violence and abuse towards NHS staff can have a devastating impact on people already under intense systemic pressure, with many now having to take time off sick or deciding they have no option but to leave their profession completely.'
Dr Fuller also spoke of 'a constant narrative that GPs are not doing what they should be' in the media.
'Yet the evidence we're getting is the experience is improving,' she told PA.
'So it has now become acceptable to bash GPs, and that's not OK.
'I'm hearing that from every GP I speak to.
'And people do leave because they've just had enough.
'It does matter when you keep reading in the press what a terrible job you're doing when you're exhausted and you've worked flat out and you haven't had any lunch – people are working really hard, and something has happened that has changed in that narrative.'
However, Dr Fuller said there have been improvements in general practice emerging.
'There's variation, but actually we're starting to see improvement around the country,' she said.
'Not only have we got more GPs, fewer GPs leaving, but we are also starting to see that patients' experience of access is starting to improve.
'It's not perfect everywhere.
'We still need to make it better, but it is starting to get better.'
Dr Fuller was speaking at a consultation event for the upcoming 10 Year Health Plan in Liverpool.
The blueprint will focus on shifting more care from hospital to the community, as well as preventing ill health and a greater use of data and technology.
She said that 'all members of primary care' will play a 'massive role' in those shifts.
It comes as new NHS figures revealed more than 316,000 pharmacy consultations for the contraceptive pill have been carried out since a scheme launched in April 2023.
Dr Fuller said: 'Contraception is terribly important, as we know.
'And for many women, contraception is an incredibly important part of just our day-to-day lives, and we need to make it just as easy as possible and not over-medicalise something that it should be part of just how you live your life.
'So actually, being able to go to the community pharmacies who are open at weekends with longer opening hours, so they don't have to take time off work to get an appointment or to phone and go by the GP, just makes it easier for people to live their lives in the way that works for them.'
Dr Fuller expects the number of women taking part in the scheme to increase in the future.
'I think it's very much word of mouth spread through different communities, so I expect it to continue to grow,' she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

Yahoo

time2 days ago

  • Yahoo

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical OfficerPhiladelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Dr. Jyothis George, M.D., Ph.D., FRCP, FACE as Chief Medical Officer, effective immediately. Jyothis brings a wealth of global leadership experience in cardiometabolic drug development, regulatory strategy and medical affairs. He joins NodThera from Amgen (NASDAQ: AMGN), where he served as Global Medical Vice President, Obesity and Related Conditions, driving strategic decision making on target indications and priority patient populations, securing investment to generate differentiating evidence and leading expert engagement. His recent responsibilities included strategic planning around MariTide, Amgen's lead candidate in obesity. Previously, Jyothis held leadership roles at Novo Nordisk (CPH: NOVO-B) and Boehringer Ingelheim, directing pivotal programs in obesity, diabetes, heart failure and chronic kidney disease. At Novo Nordisk, Jyothis was Corporate Vice President, Clinical Development, Medical Affairs and Regulatory. There he successfully delivered multiple key clinical trials across the Novo Nordisk portfolio, including major regulatory studies for several assets including semaglutide (Wegovy®) and launching impactful educational platforms such as ObesityME and the Diabetes Masters Network. At Boehringer Ingelheim, as Global Head of Clinical Development and Medical Affairs, Cardiometabolism, he led the clinical development and medical affairs teams for two blockbuster cardiometabolic assets: empagliflozin, the first diabetes treatment to gain an FDA cardiovascular mortality indication, and the DPP4 inhibitor linagliptin. During his tenure, he successfully delivered multiple global clinical trials, including serving on steering committees of six major cardiovascular outcomes trials. Daniel Swisher, Chief Executive Officer of NodThera, said: "We are thrilled to welcome Jyothis to NodThera as our Chief Medical Officer. He brings a critical combination of deep clinical and patient insight coupled to recent global leadership in cardiometabolic drug development, shaping landmark trials and delivering regulatory success. His expertise will be invaluable to NodThera as we advance our brain-penetrant NLRP3 inflammasome inhibitors further through clinical development." Jyothis George, M.D., Ph.D., FRCP, FACE, commented: "Joining NodThera provides an exciting opportunity to transform the treatment of diseases driven by chronic low-grade inflammation. I am inspired by the science and the team's bold vision to reimagine what's possible for patients by restoring the body's natural metabolic balance. Together with the team, I am looking forward to building on NodThera's promising clinical momentum to deliver therapies that are not only differentiated, but truly transformative for patients." Jyothis holds an M.B.B.S. from St. John's Medical College in Bangalore, India; a Ph.D. in Neuroendocrinology from the University of Edinburgh, and is board certified in Internal Medicine, Endocrinology and Diabetes (UK). He is a Fellow of the Royal College of Physicians (Edinburgh) and the American College of Endocrinology and has authored more than 100 peer-reviewed publications. He has previously served on the boards of Amgen Technologies Ireland and Oxford Centre for Diabetes, Endocrinology and Metabolism. For more information about NodThera please contact: NodTheraTel: +44 (0) 1223 608130Email: info@ ICR Healthcare Amber Fennell, David Daley Tel: +44 (0)20 3709 5700Email: nodthera@ About NodTheraNodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced management team, NodThera is combining a deep understanding of NLRP3 inhibition, pharmaceutical neuroscience expertise and precision chemistry. Its two lead clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors, which have demonstrated differentiated, potentially best-in-class clinical profiles with significant anti-inflammatory effects and high brain penetration, offering distinct opportunities to treat multiple indications. The Company is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Philadelphia, Pennsylvania, with additional operations in Cambridge, UK. Learn more at or follow the Company on in to access your portfolio

Single jab will offer ‘protective bubble' to premature babies this winter
Single jab will offer ‘protective bubble' to premature babies this winter

Yahoo

time4 days ago

  • Yahoo

Single jab will offer ‘protective bubble' to premature babies this winter

A single, long-lasting jab that offers a 'protective bubble' to premature babies from a common virus is set to be rolled out on the NHS in England this autumn. Experts say the drug will give thousands of vulnerable infants 'their own suit of armour' for their first winter. From late September, the health service will offer nirsevimab to protect babies born before 32 weeks against respiratory syncytial virus (RSV). The jab, which offers six months protection in a single dose, will replace monthly injections of palivizumab previously offered. RSV is a common cause of coughs and colds and usually gets better by itself, but can cause severe illness for babies and older adults. It is estimated that about 30,000 youngsters are admitted to hospital with the virus every year in the UK, with about 30 babies dying. According to NHS England, data shows premature babies are three times more likely to go to hospital with RSV and are 10 times more likely to need intensive care when compared to full-term babies. Health systems in Scotland, Wales and Northern Ireland will also offer nirsevimab from autumn, meaning about 9,000 babies in the UK are set to benefit. Dr Claire Fuller, co-national medical director for NHS England said: 'This injection will provide premature babies with a protective bubble against RSV just in time for the colder months. 'It will offer a long-lasting defence helping to avoid unnecessary hospitalisations and serious illness – giving babies the best possible start in life and shielding them from harm.' Since September 2024, pregnant women have been eligible for an RSV jab from 28 weeks onwards to boost their immune system and pass antibodies to their unborn babies to protect them in the first weeks of life. However, this new drug works differently to the jab, as premature babies born before 32 weeks have limited or no protection given from the vaccinations recommended for pregnant women. Dr Conall Watson, consultant epidemiologist at the UK Health Security Agency, said: 'Having an RSV vaccine from week 28 in every pregnancy is key to protecting your baby against RSV bronchiolitis. Most RSV hospital admissions in babies can be prevented by vaccination. 'This new NHS nirsevimab immunisation programme will offer really important protection for very premature babies born before they can be protected by mum's antenatal vaccination.' John Stewart, director of specialised commissioning at NHS England said: 'For babies born very prematurely, the risk of contracting RSV in their first winter is high and extremely serious. 'This new medication will provide vulnerable infants with their own suit of armour that protects against what can be a life-threatening infection.' Public health minister Ashley Dalton said: 'By rolling out nirsevimab this September, we're ensuring that our most at-risk infants, including those who are born too early to benefit from maternal vaccination, are protected in the best possible way.' Trial data shows nirsevimab offers more than 80% protection against RSV compared to about 55% with palivizumab, NHS England said. Nirsevimab will also be offered on a seasonal basis to babies and young children with weakened immune systems or complex heart and lung conditions.

List of patients waiting longest for hospital treatment, by deprivation area
List of patients waiting longest for hospital treatment, by deprivation area

Yahoo

time6 days ago

  • Yahoo

List of patients waiting longest for hospital treatment, by deprivation area

Here is a full list of the proportion of people waiting more than a year to start hospital treatment in the most and least deprived areas of each region and NHS trust in England. It is the first time this data has been published. The figures are for the week ending June 29 2025. The data is presented in two sections, the first giving the proportions for each region, the second giving the proportions for every NHS trust. A small number of trusts reported no data. The regions and trusts are listed alphabetically. The list has been compiled by the PA news agency using data published by NHS England. The name of the region or trust is followed by the percentage of people waiting more than a year to begin treatment in the most deprived areas, then the percentage for the least deprived areas. – Regions: East of England: 4.9% in most deprived areas, 4.0% in least deprived areasLondon: 2.4%, 1.8%Midlands: 3.0%, 2.4%North East & Yorkshire: 2.1%, 1.9%North West: 4.0%, 3.7%South East: 3.4%, 3.1%South West: 2.1%, 1.7% – NHS trusts: Airedale: 0.5% in most deprived areas, no data for least deprived areasAlder Hey Children's: 2.4%, 1.8%Ashford & St Peter's Hospitals: no data, 2.1%Barking, Havering & Redbridge University Hospitals: no data, 0.5%Barnsley: 0.7%, no dataBarts: 4.1%, 3.6%Bedfordshire: 2.4%, 2.6%Birmingham Women's & Children's: 0.9%, 1.6%Blackpool Teaching Hospitals: 5.4%, 3.7%Bolton: 3.5%, 3.3%Bradford Teaching Hospitals: 0.6%, no dataBuckinghamshire: no data, 2.7%Calderdale & Huddersfield: 0.2%, no dataCambridge University Hospitals: 3.4%, 4.3%Chelsea & Westminster: 1.4%, 1.9%Chesterfield Royal: 3.5%, 3.5%Countess of Chester: 9.9%, 8.1%County Durham & Darlington: 0.9%, 1.3%Croydon Health Services: 1.2%, 2.5%Dartford & Gravesham: 3.4%, 2.9%Doncaster & Bassetlaw Teaching Hospitals: 2.7%, 4.9%Dorset County: 1.4%, 1.9%East & North Hertfordshire: no data, 1.6%East Cheshire: no data, no dataEast Kent Hospitals University: 3.2%, 2.9%East Lancashire Hospitals: 4.1%, 4.0%East Suffolk & North Essex: 3.6%, 3.2%East Sussex: 1.8%, 1.6%Epsom & St Helier University Hospitals: no data, 1.6%Frimley: no data, 3.4%Gateshead: 0.4%, no dataGeorge Eliot Hospital: 3.6%, 3.9%Gloucestershire Hospitals: 0.0%, no dataGreat Ormond Street: 3.1%, 4.9%Great Western Hospitals: 2.0%, 1.6%Guy's & St Thomas': 2.3%, 2.0%Hampshire Hospitals: no data, 3.6%Harrogate & District: no data, no dataHomerton Healthcare: 0.7%, no dataHull University Teaching Hospitals: 3.8%, 3.0%Imperial College Healthcare: 2.1%, 2.4%Isle of Wight: no data, no dataJames Paget University Hospitals: 5.1%, 4.8%Kettering General Hospital: 1.3%, 0.9%King's College Hospital: 2.9%, 1.5%Kingston & Richmond: 0.0%, 0.6%Lancashire Teaching Hospitals: 4.0%, 2.6%Leeds Teaching Hospitals: 3.4%, 2.8%Lewisham & Greenwich: 4.7%, 5.1%Liverpool Heart & Chest Hospital: no data, 4.3%Liverpool University Hospitals: 4.9%, 2.8%Liverpool Women's: 3.5%, no dataLondon North West University: 2.7%, 2.7%Maidstone & Tunbridge Wells: 0.0%, 0.0%Manchester University: 4.6%, 3.4%Medway: 4.2%, 5.6%Mersey & West Lancashire Teaching Hospitals: 3.1%, 2.7%Mid & South Essex: 7.8%, 6.6%Mid Cheshire Hospitals: 7.0%, 4.5%Mid Yorkshire Teaching: 0.9%, 0.6%Milton Keynes University Hospital: 5.2%, 5.1%Moorfields Eye Hospital: 0.0%, no dataNorfolk & Norwich University Hospitals: 4.8%, 4.3%North Bristol: 0.4%, 0.4%North Cumbria Integrated Care: 2.9%, 3.1%North Tees & Hartlepool: 1.2%, 0.9%North West Anglia: 3.7%, 3.6%Northampton General Hospital: 1.1%, 1.2%Northern Care Alliance: 3.9%, 4.6%Northern Lincolnshire & Goole: 2.7%, 3.5%Northumbria Healthcare: no data, 0.0%Nottingham University Hospitals: 2.1%, 1.8%Oxford University Hospitals: 3.3%. 3.4%Portsmouth Hospitals University: 4.8%, 4.1%Queen Victoria Hospital: 3.8%, 1.7%Royal Berkshire: no data, no dataRoyal Cornwall Hospitals: 1.0%, no dataRoyal Devon University Healthcare: 4.1%, 2.6%Royal Free London: 3.3%, 2.9%Royal National Orthopaedic Hospital: no data, 1.1%Royal Papworth Hospital: no data, 1.4%Royal Surrey County Hospital: no data, 5.2%Royal United Hospitals Bath: 2.5%, 2.0%Salisbury: no data, 0.7%Sandwell & West Birmingham Hospitals: 1.9%, 1.4%Sheffield Children's: 2.9%, 2.1%Sheffield Teaching Hospitals: 2.3%, 2.2%Sherwood Forest Hospitals: 1.6%, 1.0%Somerset: 3.0%, 2.9%South Tees Hospitals: 3.4%, 3.1%South Tyneside & Sunderland: no data, 0.0%South Warwickshire University: 7.1%, 2.2%St George's University Hospitals: 5.1%, 2.2%Stockport: 3.8%, 3.0%Surrey & Sussex Healthcare: no data, 1.7%Tameside & Glossop Integrated Care: 0.0%, 0.0%The Christie: 0.0%, 0.0%The Clatterbridge Cancer Centre: 0.0%, 0.0%The Dudley Group: 1.3%, 0.9%The Hillingdon Hospitals: 0.0%, 1.4%The Newcastle upon Tyne Hospitals: 1.5%, 1.5%The Princess Alexandra Hospital: no data, 5.3%The Queen Elizabeth Hospital King's Lynn: 2.3%, no dataThe Robert Jones & Agnes Hunt Orthopaedic Hospital: 7.8%, 9.1%The Rotherham: 2.3%, no dataThe Royal Marsden: 0.0%, no dataThe Royal Orthopaedic Hospital: 3.9%, 3.6%The Royal Wolverhampton: 3.9%, 2.7%The Shrewsbury & Telford Hospital: 2.3%, 2.4%The Walton Centre: 0.8%, 1.4%Torbay & South Devon: 2.8%, 2.5%United Lincolnshire Teaching Hospitals: 2.9%, 3.0%University College London Hospitals: 2.3%, 1.9%University Hospital Southampton: 2.5%, 2.1%University Hospitals Birmingham: 5.9%, 4.8%University Hospitals Bristol & Weston: 1.4%, 1.5%University Hospitals Coventry & Warwickshire: 2.8%, 3.1%University Hospitals Dorset: 3.5%, 3.2%University Hospitals of Derby & Burton: 1.9%, 2.0%University Hospitals of Leicester: 2.7%, 2.0%University Hospitals of Morecambe Bay: 1.8%, 1.0%University Hospitals of North Midlands: 2.9%, 2.2%University Hospitals Plymouth: 3.8%, 3.8%University Hospitals Sussex: 6.0%, 5.1%Walsall Healthcare: 0.2%, no dataWarrington & Halton Teaching Hospitals: 5.2%, 4.7%West Hertfordshire Teaching Hospitals: no data, 1.7%West Suffolk: 8.7%, 4.4%Whittington Health: 1.3%, no dataWirral University Teaching Hospital: 3.1%, 2.3%Worcestershire Acute Hospitals: 2.1%, 1.5%Wrightington, Wigan & Leigh: 3.9%, 3.9%Wye Valley: 3.8%, 2.7%York & Scarborough Teaching Hospitals: 3.2%, 2.7%

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store